Synchron Raises $200M to Advance Brain-Computer Interface
Synchron has secured $200 million to accelerate pivotal trials and prepare for the commercial launch of its Stentrode brain-computer interface (BCI) system.
Brain-Computer Interface Technology Overview
BCI companies develop devices that capture and interpret brain signals to trigger actions like hands-free control of digital devices. There are major differences among devices based on invasiveness and signal fidelity.
Comparison of BCI Devices
- Elon Musk’s Neuralink implants its device by removing part of the skull.
- Synchron’s Stentrode is implanted via a less invasive catheter procedure.
- Synchron’s first-generation Stentrode has 16 electrodes, while Neuralink’s N1 Implant has 1,024 electrodes.
Despite fewer electrodes, the Stentrode enables severely paralyzed individuals to control personal devices effectively.
Strategic Use of Funds
The Series D funding empowers Synchron to capitalize on its first-generation device's benefits while addressing its implant limitations for the future. The company plans to:
- Speed up pivotal clinical trials.
- Prepare for the commercial launch of the Stentrode system.
- Develop a next-generation, high-channel whole-brain interface delivered through a transcatheter method.
Artificial Intelligence Integration
Synchron is expanding its AI team in New York City to build models that decode brain data in real time. Artificial intelligence plays a key role in interpreting thoughts for immediate response.
"Synchron’s goal is to decode thought in real time."
Author’s summary: Synchron’s $200M raise aims to fast-track trials and launch of a catheter-implanted brain interface, with AI enhancing real-time thought decoding.